Journal article
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma
B Dréno, PA Ascierto, V Atkinson, G Liszkay, M Maio, M Mandalà, L Demidov, D Stroyakovskiy, L Thomas, L De La Cruz-Merino, C Dutriaux, C Garbe, K Bartley, T Karagiannis, I Chang, I Rooney, DO Koralek, J Larkin, GA McArthur, A Ribas
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2018
DOI: 10.1038/bjc.2017.488
Abstract
Background: In the coBRIM study, cobimetinib plus vemurafenib (C+V) significantly improved survival outcomes vs placebo and vemurafenib (P+V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis of health-related quality of life (HRQOL) from coBRIM is reported. Methods: Patients completing the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline and X1 time point thereafter constituted the analysis population. Change from baseline X10 points was considered clinically meaningful. Results: Mean baseline scores for all QLQ-C30 domains were similar between arms. Most on-treatment scores for QLQ-C30 domains w..
View full abstractGrants
Funding Acknowledgements
This study was funded by F. Hoffmann-La Roche Ltd. Third-party medical writing assistance was provided by Melanie Sweetlove, MSc, and Jerome Sah, PhD (ApotheCom, San Francisco, CA, USA) and was funded by F. Hoffmann-La Roche Ltd.